An anti-PD-L1 nanobody, a bispecific recombinant protein containing it, and their applications
By developing camel-like nanobodies that bind to the constant region of human IgG to form bispecific recombinant proteins, the problems of high cost and heavy chain mismatch of traditional PD-L1 antibodies have been solved, achieving efficient and safe tumor suppression effects.
Patent Information
- Application Number
- CN202511627905.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-07
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-11-07
AI Technical Summary
Existing traditional PD-L1 antibodies are expensive, require large dosages, and suffer from heavy-light chain mismatch issues during development. They also have large molecular weights, moderate affinity, and low cross-reactivity with different species.
Using antibodies from camel-like animals, a low molecular weight nanobody was developed, containing a VHH domain and a CDR region. By binding to the constant region of human IgG, a bispecific recombinant protein was formed to block the PD-1/PD-L1 signaling pathway. When combined with the CTLA-4 nanobody, the tumor suppression effect was improved.
Nanobodies can exert tumor-suppressing effects at low doses, have high stability and strong affinity, can effectively block PD-1/PD-L1 binding, improve tumor suppression effects, and have species cross-reactivity, high expression levels, and higher safety.
Smart Images

Figure CN121609799B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of immunology and relates to an anti-PD-L1 nanobody, a bispecific recombinant protein containing it, and their applications. Background Technology
[0002] Tumor immunotherapy mainly includes monoclonal antibody immune checkpoint inhibitors, tumor vaccines, cell immunotherapy, and small molecule inhibitors. Currently, the main antibody drugs under development for tumor immunotherapy internationally focus on immune checkpoint inhibitors, especially monoclonal antibody drugs such as PD-1 and CTLA-4. PD-1 (programmed cell death protein 1) is an important immunosuppressive molecule, belonging to the immunoglobulin superfamily, and is mainly expressed on the surface of immune cells such as T cells. PD-1 has two ligands: programmed cell death 1 ligand 1 (PD-L1) and programmed cell death 1 ligand 2 (PD-L2). The PD-1 / PD-L1 signaling pathway plays an important role in the regulation of immune tolerance, microbial infection, and tumor immune escape. PD-L1 can transmit inhibitory signals by binding to PD-1 or B7-1, thereby reducing the proliferation of antigen-specific T cells in lymph nodes and reducing the apoptosis of regulatory T cells (anti-inflammatory and suppressive T cells). In addition, PD-1 can also control the accumulation of antigen-specific T cells in lymph nodes by regulating the Bcl-2 gene.
[0003] Currently, PD-L1 is found to be highly expressed in many human tumor tissues and cells. By blocking the PD-1 / PD-L1 signaling pathway and preventing PD-1 from binding to PD-L1 on the tumor surface, the expression of activation markers on the T cell surface can be upregulated, thereby promoting the proliferation of tumor antigen-specific T cells, restoring the anti-tumor immune function of the tumor microenvironment, and killing tumor cells to inhibit local tumor growth. This has become the biggest hot topic in tumor immunotherapy in recent years, suitable for various types of malignant tumors, such as melanoma, liver cancer, lung cancer, gastrointestinal tumors, breast cancer, bladder cancer, and sarcoma. Currently, PD-1 and PD-L1 monoclonal antibody drugs on the market, such as Opdivo (nivolumab, PD-1 monoclonal antibody), Keytruda (pembrolizumab, PD-1 monoclonal antibody), Tensentriq (atezilumab, PD-L1 monoclonal antibody), and Avelumab (avelumab, PD-L1 monoclonal antibody), are all imported drugs and are expensive. Currently, there are four domestically produced PD-1 monoclonal antibody drugs on the market in China, but as of now, there are no domestically produced monoclonal antibody drugs specifically targeting PD-L1. Due to the subtle differences in the mechanisms of action between PD-L1 antibodies and PD-1 antibodies, blocking specific PD-L1 immune checkpoints on target cells, PD-L1 antibody-based therapies or combination therapies may be safer and have greater development potential.
[0004] Most existing traditional PD-L1 antibodies are imported, expensive, and require relatively large doses. The PD-L1 antibody in this invention can exert its tumor-suppressing effect at a lower dose, which also increases safety to some extent. Furthermore, unlike traditional PD-L1 heavy and light chain antibodies on the market, antibodies from camels are heavy chain antibodies with naturally missing light chains. The variable region VHH in heavy chain antibodies is the smallest antigen-binding fragment, also known as a nanobody. Nanobodies are typically only one-tenth the size of traditional antibodies, approximately 15 kDa. They contain disulfide bonds internally and have numerous hydrophilic residues on their surface, exhibiting high stability and strong resistance to heat and pH. They can be stored at room temperature or used for oral absorption without degradation, thus broadening the possible formulations and applications of antibodies. Compared with traditional PD-L1 antibodies, the PD-L1 nanobodies of this invention are easier to modify into functional antibodies. For example, by combining them with two or more other target nanobodies, they can be developed into bispecific or multispecific antibodies. This can avoid problems such as heavy / light chain mismatch that occur in the development of traditional bispecific / multispecific antibodies. At the same time, their molecular weight is suitable, and the molecular weight of the bispecific antibody modified into it does not exceed that of the traditional antibody. Moreover, it is simple to manufacture and has greater potential for application development. Summary of the Invention
[0005] To address the shortcomings of existing technologies, traditional PD-L1 antibodies are mainly large-molecule full-length antibodies with relatively high dosage, moderate affinity, and low cross-reactivity with species, this invention provides an anti-PD-L1 nanobody, a bispecific recombinant protein containing it, and their applications.
[0006] Specifically, the present invention solves the above-mentioned technical problems through the following technical solutions.
[0007] A first aspect of the present invention provides an anti-PD-L1 nanobody, the nanobody comprising a VHH domain, the VHH domain comprising CDR1, CDR2 and CDR3; wherein the amino acid sequence of the CDR3 is shown in SEQ ID NO: 48;
[0008] SEQ ID NO: 48 is shown below:
[0009] AARX1GMMALATHRALYEX2, where X1 is N or R, and X2 is E or Y;
[0010] Furthermore, the amino acid sequences of CDR1 and CDR2 are shown in SEQ ID NO: 4 and 8, respectively;
[0011] Alternatively, the amino acid sequences of CDR1 and CDR2 are shown in SEQ ID NO: 1 and 5, respectively;
[0012] Alternatively, the amino acid sequences of CDR1 and CDR2 are shown in SEQ ID NO: 1 and 6, respectively;
[0013] Alternatively, the amino acid sequences of CDR1 and CDR2 are shown in SEQ ID NO: 2 and 7, respectively;
[0014] Alternatively, the amino acid sequences of CDR1 and CDR2 are shown in SEQ ID NO: 3 and 5, respectively.
[0015] In some embodiments, the amino acid sequence of the CDR3 is as shown in any of SEQ ID NO: 9-11.
[0016] In some specific embodiments, the amino acid sequences of CDR1-CDR3 are shown in SEQ ID NO: 4, 8 and 10, respectively.
[0017] In some specific embodiments, the amino acid sequences of CDR1-CDR3 are shown as SEQ ID NO: 1, 5 and 9, respectively.
[0018] In some specific embodiments, the amino acid sequences of CDR1-CDR3 are shown in SEQ ID NO: 1, 6 and 10, respectively.
[0019] In some specific embodiments, the amino acid sequences of CDR1-CDR3 are shown in SEQ ID NO: 2, 7 and 11, respectively.
[0020] In some specific embodiments, the amino acid sequences of CDR1-CDR3 are shown as SEQ ID NO: 3, 5 and 10, respectively.
[0021] In some embodiments, the VHH domain further comprises FR1, FR2, FR3 and FR4; wherein FR1 comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the amino acid sequence shown as in SEQ ID NO: 12 or 13.
[0022] In some embodiments, the FR2 comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with an amino acid sequence as shown in any of SEQ ID NO: 14-16.
[0023] In some embodiments, the FR3 comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with an amino acid sequence as shown in any of SEQ ID NO: 17-21.
[0024] In some embodiments, the FR4 comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 22.
[0025] In some embodiments, the FR1 comprises an amino acid sequence as shown in SEQ ID NO: 12 or 13.
[0026] In some embodiments, the FR2 comprises an amino acid sequence as shown in any of SEQ ID NO: 14-16.
[0027] In some embodiments, the FR3 comprises an amino acid sequence as shown in any of SEQ ID NO: 17-21.
[0028] In some embodiments, the FR4 comprises an amino acid sequence as shown in SEQ ID NO: 22.
[0029] In some embodiments, FR1-FR4 respectively comprise the amino acid sequences shown in SEQ ID NO: 12, 14, 21 and 22; or, respectively comprise the amino acid sequences shown in SEQ ID NO: 12, 14, 17 and 22; or, respectively comprise the amino acid sequences shown in SEQ ID NO: 12, 14, 18 and 22; or, respectively comprise the amino acid sequences shown in SEQ ID NO: 12, 15, 19 and 22; or, respectively comprise the amino acid sequences shown in SEQ ID NO: 13, 16, 21 and 22.
[0030] In some embodiments, the nanobody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with an amino acid sequence as shown in any of SEQ ID NO: 23-27.
[0031] In some specific embodiments, the nanobody comprises an amino acid sequence as shown in any of SEQ ID NO: 23-27.
[0032] A second aspect of the present invention provides a fusion protein comprising a nanobody as described in the first aspect of the present invention.
[0033] In some embodiments, the fusion protein is selected from one or more of the following:
[0034] (i) Monovalent or multivalent nanobodies;
[0035] (ii) Bispecific antibodies or multispecific antibodies;
[0036] (iii) Heavy chain antibodies.
[0037] In some implementations, the fusion protein includes a heavy chain constant region.
[0038] In some implementations, the heavy chain constant region is the heavy chain constant region of human IgG1, IgG2, IgG3 or IgG4.
[0039] In some embodiments, the heavy chain constant region comprises CH2-CH3 or CH1-CH2-CH3.
[0040] In some embodiments, the heavy chain constant region comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 50.
[0041] In some specific embodiments, the heavy chain constant region contains an amino acid sequence as shown in SEQ ID NO: 50.
[0042] A third aspect of the present invention provides a bispecific recombinant protein comprising a first protein functional region and a second protein functional region targeting PD-L1; the first protein functional region comprising a nanobody as described in the first aspect of the present invention.
[0043] In some implementations, the second protein functional region is selected from full-length antibodies, Fab, Fab', F(ab')2, Fv, scFv, and sdAb.
[0044] In some implementations, the second protein functional region targets CTLA-4.
[0045] In some embodiments, the second protein functional region is sdAb, which contains a VHH' domain.
[0046] In some embodiments, the VHH' comprises CDR1', CDR2', and CDR3'; wherein the amino acid sequences of CDR1'-CDR3' are as shown in SEQ ID NO: 37-39, respectively.
[0047] In some embodiments, the VHH' comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 36.
[0048] In some specific embodiments, the VHH' comprises an amino acid sequence as shown in SEQ ID NO: 36.
[0049] In some embodiments, the bispecific recombinant protein includes constant regions selected from human IgG1, IgG2, IgG3, IgG4 and variants thereof, wherein the variants have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the sequence from which they are derived.
[0050] In some embodiments, the bispecific recombinant protein includes a constant region derived from human IgG4 or a variant thereof.
[0051] In some implementations, the variant is a constant region of human IgG4 or human IgG1 with both knockb and hole mutations.
[0052] In some embodiments, the bispecific recombinant protein comprises two chains having one of the following structures:
[0053] (1) Chain I: VHH-CH2CH3-VHH'; Chain II: VHH-CH2CH3-VHH';
[0054] (2) Chain I: VHH-VHH'-CH2CH3; Chain II: VHH-VHH'-CH2CH3;
[0055] (3) Chain I: VHH-VHH-CH2CH3; Chain II: VHH'-VHH'-CH2CH3;
[0056] Among them, the C end of VHH or VHH' is connected to the N end of the constant region through a hinge region; the N end of VHH or VHH' is connected to the C end of the constant region through a connector; VHH and VHH' are connected to each other through a connector.
[0057] In some embodiments, the linker comprises an amino acid sequence as shown in SEQ ID NO: 51.
[0058] In some embodiments, the hinge region comprises an amino acid sequence as shown in SEQ ID NO: 49.
[0059] In some embodiments, the two chains of the bispecific recombinant protein are identical and contain an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 32 or 33; or, the two chains of the bispecific recombinant protein are different, with chain I containing an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 34, and chain II containing an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 35.
[0060] In some specific embodiments, the two chains of the bispecific recombinant protein are identical and contain the amino acid sequence shown in SEQ ID NO: 32 or 33; or, the two chains of the bispecific recombinant protein are different, with chain I containing the amino acid sequence shown in SEQ ID NO: 34 and chain II containing the amino acid sequence shown in SEQ ID NO: 35.
[0061] A fourth aspect of the present invention provides an isolated nucleic acid that encodes a nanobody as described in the first aspect of the present invention, a fusion protein as described in the second aspect, or a bispecific recombinant protein as described in the third aspect.
[0062] A fifth aspect of the present invention provides a recombinant vector comprising the nucleic acid as described in the fourth aspect of the present invention.
[0063] In some embodiments, the recombinant vector is selected from viral vectors and non-viral vectors; the non-viral vector is selected from plasmids, linear DNA fragments, and RNA.
[0064] A sixth aspect of the present invention provides a transformant comprising a nucleic acid as described in the fourth aspect of the present invention, or a recombinant vector as described in the fifth aspect of the present invention; and the transformant is not an animal or plant species.
[0065] In some embodiments, the host cell of the transformant is a prokaryotic cell or a eukaryotic cell.
[0066] In some embodiments, the eukaryotic cells are yeast cells or mammalian cells.
[0067] A seventh aspect of the present invention provides a method for preparing nanobodies, fusion proteins, or bispecific recombinant proteins, the method comprising culturing a transformant as described in the sixth aspect of the present invention under suitable conditions, and obtaining the nanobodies, fusion proteins, or bispecific recombinant proteins from the culture.
[0068] The eighth aspect of the present invention provides an antibody-drug conjugate having the structure shown in Formula I below:
[0069] Ab-[(L2) n -L1-D] y Formula I;
[0070] Wherein, D is a small molecule drug with cytotoxicity, L1 and L2 are linkers connecting the drug and the antibody, respectively; n is 0 or 1; y represents the average number of D coupled to the antibody, and 0 < y ≤ 10;
[0071] The Ab is a nanobody as described in the first aspect of the present invention, a fusion protein as described in the second aspect, or a bispecific recombinant protein as described in the third aspect.
[0072] In some implementations, 2≤y≤7.
[0073] In some implementations, 3≤y≤6.
[0074] In some embodiments, the small molecule drug is one or more of MMAE, MMAF, DM1, DM3, and DM4; and the linker is one or more of SPP, SIAB, SMCC, MP, VC, ala-phe, PAB, and MC-VC-PAB.
[0075] A ninth aspect of the present invention provides a chimeric antigen receptor comprising (a) an antigen-binding domain, including nanobodies as described in the first aspect of the present invention, fusion proteins as described in the second aspect, or bispecific recombinant proteins as described in the third aspect.
[0076] In some embodiments, the chimeric antigen receptor further includes one or more of: (b) a hinge domain; (c) a transmembrane domain; (d) a co-stimulatory intracellular domain; (e) a signal transduction domain; and (f) a signal peptide.
[0077] The tenth aspect of the present invention provides a genetically modified cell comprising a chimeric antigen receptor as described in the ninth aspect of the present invention.
[0078] In some implementations, the host cell of the genetically modified cell is a T cell or an NK cell.
[0079] The eleventh aspect of the present invention provides a pharmaceutical composition comprising at least one of the following: a nanobody as described in the first aspect of the present invention, a fusion protein as described in the second aspect, a bispecific recombinant protein as described in the third aspect, an antibody-drug conjugate as described in the eighth aspect, a chimeric antigen receptor as described in the ninth aspect, or a genetically modified cell as described in the tenth aspect, and a pharmaceutically acceptable carrier, excipient, or diluent.
[0080] The twelfth aspect of the present invention provides a kit comprising a nanobody as described in the first aspect of the present invention, a fusion protein as described in the second aspect, a bispecific recombinant protein as described in the third aspect, a nucleic acid as described in the fourth aspect, a recombinant vector as described in the fifth aspect, a transformant as described in the sixth aspect, an antibody-drug conjugate as described in the eighth aspect, a chimeric antigen receptor as described in the ninth aspect, a genetically modified cell as described in the tenth aspect, or a pharmaceutical composition as described in the eleventh aspect.
[0081] The thirteenth aspect of the present invention provides a method for detecting PD-L1, the method comprising contacting a sample to be tested with a nanobody as described in the first aspect of the present invention, a fusion protein as described in the second aspect of the present invention, or a kit as described in the twelfth aspect of the present invention.
[0082] In some implementations, the method is for non-diagnostic and / or therapeutic purposes.
[0083] The fourteenth aspect of the present invention provides the use of nanobodies as described in the first aspect of the present invention, fusion proteins as described in the second aspect, bispecific recombinant proteins as described in the third aspect, nucleic acids as described in the fourth aspect, recombinant vectors as described in the fifth aspect, transformants as described in the sixth aspect, antibody-drug conjugates as described in the eighth aspect, chimeric antigen receptors as described in the ninth aspect, genetically modified cells as described in the tenth aspect, or pharmaceutical compositions as described in the eleventh aspect, or kits as described in the twelfth aspect, in the preparation of medicaments for the prevention and / or treatment of PD-L1-related diseases.
[0084] In some implementations, the PD-L1-related disease is a tumor or cancer, preferably selected from colon cancer, lung cancer, melanoma, and gastric cancer.
[0085] The fifteenth aspect of the present invention provides a method for preventing and / or treating PD-L1-related diseases, the method comprising administering to a subject in need a preventive and / or therapeutically effective amount of, as described in the first aspect of the present invention, a fusion protein as described in the second aspect, a bispecific recombinant protein as described in the third aspect, a nucleic acid as described in the fourth aspect, a recombinant vector as described in the fifth aspect, a transformant as described in the sixth aspect, an antibody-drug conjugate as described in the eighth aspect, a chimeric antigen receptor as described in the ninth aspect, a genetically modified cell as described in the tenth aspect, a pharmaceutical composition as described in the eleventh aspect, or a kit as described in the twelfth aspect.
[0086] In some implementations, the PD-L1-related disease is a tumor or cancer, preferably selected from colon cancer, lung cancer, melanoma, and gastric cancer.
[0087] The sixteenth aspect of the present invention provides nanobodies as described in the first aspect of the present invention, fusion proteins as described in the second aspect, bispecific recombinant proteins as described in the third aspect, nucleic acids as described in the fourth aspect, recombinant vectors as described in the fifth aspect, transformants as described in the sixth aspect, antibody-drug conjugates as described in the eighth aspect, chimeric antigen receptors as described in the ninth aspect, genetically modified cells as described in the tenth aspect, pharmaceutical compositions as described in the eleventh aspect, or kits as described in the twelfth aspect, for the prevention and / or treatment of PD-L1-related diseases.
[0088] In some implementations, the PD-L1-related disease is a tumor or cancer, preferably selected from colon cancer, lung cancer, melanoma, and gastric cancer.
[0089] Based on common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.
[0090] The reagents and raw materials used in this invention are all commercially available.
[0091] The positive and progressive effects of this invention are as follows:
[0092] The nanobody provided by this invention is the VHH variable region of a heavy chain antibody. It has a small molecular weight, high stability, and can effectively block the binding of PD-1 to PD-L1 with high affinity. Furthermore, the nanobody can be fused with a human Fc fragment to form a bivalent antibody. This bivalent nanobody can be stably expressed in large quantities in eukaryotic mammalian cells, with an initial expression level of 150-300 mg / L, exhibiting extremely high expression efficiency and stability. The affinity, PBMC activation, and tumor-suppressive effect of the bivalent antibody are similar to those of the existing commercial PD-L1 antibody Tecentriq, and it has a stronger inhibitory effect on the binding of PD-L1 target cells and PD-1 effector cells than the existing commercial PD-L1 antibody Avelumab. However, the nanobody also possesses species cross-reactivity and requires a lower drug dose. Constructing the PD-L1 nanobody and CTLA-4 nanobody of this invention into a bispecific antibody form can effectively improve the inhibitory effect on PD-L1-related tumors. Attached Figure Description
[0093] Figure 1 The purified PD-L1 nanobody was detected by SDS-PAGE electrophoresis; where: 1 is VHH15-4; 2 is VHH15-2; 3 is VHH15-6; 4 is VHH15-9; 5 is VHH15-8; 6 is VHH15-1; 7 is VHH15-5; 8 is VHH15-5; 9 is VHH15-7.
[0094] Figure 2 To competitively analyze the blocking effect of PD-L1 nanobodies on PD-1 / PD-L1, VHH15-1, VHH15-2, VHH15-3, VHH15-4, and VHH15-8 significantly blocked the binding of PD-1 to PD-L1 at concentrations of 3 μg / mL and 0.3 μg / mL, and effectively blocked the PD-1 / PD-L1 protein interaction even at concentrations as low as 0.03 μg / mL. VHH15-5, VHH15-6, VHH15-7, and VHH15-9 showed no blocking effect.
[0095] Figure 3To detect the antigen-binding affinity of the nanobody PD-L1.
[0096] Figure 4 This is the sequence alignment result of the nanobody.
[0097] Figure 5 Gel image of eukaryotic expression of PD-L1 bivalent nanobody; where: 1 is VHH15-1-FC; 2 is VHH15-2-FC; 3 is VHH15-3-FC; 4 is VHH15-4-FC; 5 is VHH15-8-FC.
[0098] Figure 6 The activation effect of PD-L1 monoclonal antibody on PBMCs; Blank: blank well, without OKT3 and other drugs; NC: containing OKT3, without other PD-L1 antibody drugs; PC: 1000pg / mL IFN-γ standard.
[0099] Figure 7 Tumor volume changes in subcutaneous MC38-hPDL1 colon cancer models in different groups of C57BL / 6-hPDL1 mice; data are expressed as mean ± SEM, BIW3-4: 6 administrations in total; **: P = 0.005527 < 0.01; mpk: mg per 1 kg of mouse body weight; Tumor volume: tumor volume; Tumor growth inhibition: tumor growth inhibition; TGI: tumor inhibition rate.
[0100] Figure 8 A schematic diagram of the design of a bispecific nanobody.
[0101] Figure 9 SDS-PAGE assay of bispecific nanobodies and their parental monoclonal antibodies.
[0102] Figure 10 For in vitro cell function testing of BsAb-F1.
[0103] Figure 11 The inhibitory effect of different doses of BsAb-F1 on mouse tumor growth; tumor volume growth curves (Part A) and mouse body weight change curves (Part B) under different doses of BsAb-F1; (Part C) mouse pharmacodynamic design. Tumor weight (Part D) and tumor images (Part E) at the experimental endpoint (day 34) in different treatment groups. One mouse in group G1 had a tumor volume exceeding 3000 mm on day 28. 3 In the case of euthanasia, the tumor completely disappeared in one mouse in group G4 on day 21. All data are presented as mean ± standard error (n=6), * P < 0.05, ** P < 0.01 and > 0.001. Detailed Implementation
[0104] To better understand this invention, some terms are first defined. Other definitions are listed throughout the detailed description section.
[0105] The term "antibody" refers to any form of antibody that has the desired biological activity. Therefore, it is used in the broadest sense and specifically includes, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, fully human antibodies, chimeric antibodies, and camel-derived single-domain antibodies.
[0106] The term "anti-PD-L1 nanobody" refers to an antibody that can bind to human PD-L1 with sufficient affinity, making it usable as a diagnostic and / or therapeutic agent targeting human PD-L1.
[0107] The terms "bispecific antibody" or "multispecific antibody," used in their broadest sense, encompass antibodies that exhibit multi-epitope specificity. These multispecific antibodies include, but are not limited to: antibodies comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH-VL unit exhibits multi-epitope specificity; antibodies having two or more VL and VH regions, each VH-VL unit binding to a different target or a different epitope of the same target; antibodies having two or more single variable regions, each single variable region binding to a different target or a different epitope of the same target; full-length antibodies, antibody fragments, bispecific antibodies (diabodies), and triabodies, antibody fragments covalently or non-covalently linked, etc.
[0108] The Fc region of the bispecific antibody of the present invention can be a human Fc region. The Fc region of the bispecific antibody of the present invention can be of any isotype, including but not limited to IgG1, IgG2, IgG3, or IgG4. In some embodiments, the Fc regions are all of the IgG1 isotype. In some embodiments, one of the Fc regions of the antibody is of the IgG1 isotype and the other is of the IgG4 isotype.
[0109] The "Fc region" includes the native Fc region and variant Fc regions. The native immunoglobulin "Fc domain" contains two or three constant domains: a CH2 domain, a CH3 domain, and an optional CH4 domain. Two Fc regions can dimerize to form a dimer Fc, and two different Fc regions can heterodimerize to form a heterodimeric Fc. Known methods in this field for promoting heterodimerization of Fc regions include: the "knob-into-hole (KIH)" technique proposed by Cater et al., the DuoBody platform technology from Genmab, the charge network-based Fc modification method from Suzhou Corning Jereh Co., Ltd. (CN201110459100.7) to obtain heterodimeric proteins, and other genetic engineering techniques based on Fc amino acid changes or functional modifications to achieve the formation of heterodimeric functional proteins.
[0110] The "knob-into-hole" technique refers to mutating the hydrophobic amino acids in the CH3 region of the antibody's Fc domain. To enhance hydrophobic interaction, the side-chain amino acids of one CH3 chain are mutated into larger hydrophobic amino acids (knobs), while to reduce steric hindrance, the side-chain amino acids of the other CH3 chain are mutated into smaller amino acids (holes). After mutation, the CH3 of the knockb and the CH3 of the hole form a knockb-into-hole (KIH) structure through hydrophobic interaction, which is conducive to the formation of heavy chain heterodimers. KIH mutations mainly occur on the hydrophobic amino acids inside the CH3 domain, and the amino acids exposed on the outside remain almost unchanged after mutation, therefore it does not affect the effector function of the Fc region or induce immunogenicity. The term "knob-mutation" refers to introducing point mutations such as T366W into the antibody Fc region to form a knockb-like spatial structure. Correspondingly, "hole-mutation" refers to introducing point mutations such as T366S, L368A, and Y407V into the antibody Fc region to form a hole-like spatial structure.
[0111] The term "identity" refers to the sequence matching between two polypeptides or two nucleic acids. When a position in two compared sequences is occupied by the same base or amino acid monomer subunit, the molecules are identical at that position. The "percentage identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared multiplied by 100. For example, if eight out of ten positions in two sequences match, then the two sequences have 80% identity. Typically, two sequences are compared to produce maximum identity. To determine the percentage of sequence identity, alignment can be performed using techniques known in the art, such as publicly available computer software like BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine the parameters suitable for measuring alignment, including any algorithms required to achieve maximum alignment across the full length of the compared sequences.
[0112] "Bispecific antibody," "bispecific antibody," or "bispecific recombinant protein" refers to an antibody that has binding specificity to two different antigens (or epitopes). It contains antigen-binding domains that are specific to different antigens (or epitopes), for example, two antigen-binding domains that are specific to different antigens (or epitopes), thereby enabling it to bind to two different binding sites and / or target molecules. The individual antigen-binding domains of a bispecific antibody can be independently selected from a full-length antibody (e.g., IgG antibody) or its antigen-binding fragments (e.g., Fab, Fab', F(ab')2, scFab, Fv, or scFv).
[0113] The term "variable region" refers to the domain in the antibody heavy or light chain involved in antibody binding to the antigen. VH and VL each contain four conserved frame regions (FRs) and three complementarity-determining regions (CDRs). The terms "complementarity-determining region" or "CDR" refer to the region within the variable domain that primarily facilitates antigen binding; "frame" or "FR" refers to the variable domain residues other than the CDR residues. VH contains three CDR regions: HCDR1, HCDR2, and HCDR3; VL contains three CDR regions: LCDR1, LCDR2, and LCDR3. Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDR sequence in a specific variable region can be determined using schemes known in the art, such as the Kabat, AbM, Chothia, Contact, and IMGT schemes, to define the regional range and combinations of CDRs. Unless otherwise stated, in this invention, when referring to the position of residues in the antibody variable region and CDR (including heavy chain variable region residues), it means the numbering position according to the IMGT numbering system.
[0114] The term "epitope" refers to a region on an antigen that can specifically bind to an antibody. Epitopes can be formed from a continuous string of amino acids (linear epitopes) or contain discontinuous amino acids (conformal epitopes), such as those spatially proximal due to antigen folding (i.e., tertiary folding of antigens as proteins). The difference between conformational and linear epitopes is that antibody binding to a conformational epitope is lost in the presence of a denaturing solvent. An epitope contains at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation. Screening for antibodies that bind to a specific epitope (i.e., those that bind the same epitope) can be performed using methods routine in the art, such as, but not limited to, alanine scanning, peptide blotting (see Meth. Mol. Biol. 248 (2004) 443-463).
[0115] The term "specific binding" refers to an antibody binding to an antigen or an epitope within that antigen with a higher affinity than it would to other antigens or epitopes. However, antibodies that specifically bind to an antigen or an epitope within an antigen may exhibit cross-reactivity with other related antigens, for example, cross-reactivity with the same antigens from other species (homologous) such as humans or monkeys, such as the cynomolgus (cyno), chimpanzee (chimp), or common marmoset (marmoset).
[0116] The term "affinity" refers to the overall strength of the non-covalent interaction between a single binding site of a molecule (e.g., an antibody) and its binding ligand (e.g., an antigen).
[0117] The term "EC" 50 The half-maximal effect concentration (WMP) is the antibody concentration that produces a 50% maximum effect and can be measured using methods known in the art.
[0118] The term "nucleic acid molecule" or "nucleic acid" is intended to include both DNA and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded and can be cDNA.
[0119] The term "host cell" refers to a cell in which the vector can proliferate and whose DNA can be expressed; said cell can be a prokaryotic or eukaryotic cell. The term also includes any progeny of the tested host cell. It should be understood that not all progeny are identical to the parent cell, as mutations can occur during replication; such progeny are included.
[0120] The term "transformer" refers to a host cell in which foreign DNA has been successfully introduced and stably maintained. For example, a recombinant cell formed by integrating plasmid DNA into a host cell through transformation (bacteria) or transfection (eukaryotic cells) techniques is called a transformer.
[0121] The term "antibody drug conjugate" (ADC) herein refers to a molecule formed by conjugating one or more immunoglobulin-associated molecules or fragments thereof with one or more other molecules. A conjugate typically contains at least one non-protein chemical structural part, such as a chemical linker for achieving the conjugation. In some cases, the other molecules may be the same as immunoglobulin-associated molecules or fragments thereof. In some cases, the other molecules may be different from immunoglobulin-associated molecules or fragments thereof. The one or more additional molecules may be the same as or different from each other. For example, the other molecules may be target-binding elements and / or effector elements, such as chemotherapeutic agents, toxins, drugs (e.g., immunotherapeutic agents), radioactive elements, probes, or signaling molecules.
[0122] The term "pharmaceutically acceptable" means that it can be administered to an individual or subject without producing biologically or otherwise undesirable side effects, such as serious, intolerable side effects.
[0123] The term "pharmaceuticalally acceptable carrier" refers to all substances contained in a pharmaceutical preparation other than the active pharmaceutical ingredient, generally divided into two main categories: excipients and additives. It has the same meaning as "pharmaceuticalally acceptable excipient" and can be used interchangeably.
[0124] The term “treatment” refers to a therapeutic approach or a remission measure. When a specific condition is involved, treatment means: (1) alleviating one or more biological manifestations of the disease or condition; (2) interfering with (a) one or more points in a biological cascade that causes or precipitates the condition or (b) one or more biological manifestations of the condition; (3) improving one or more symptoms, effects or side effects associated with the condition; or (4) slowing the development of the disease or one or more biological manifestations of the condition.
[0125] The term "prevention" includes the suppression of the occurrence or development of a disease or condition, or symptoms of a particular disease or condition. In some implementations, subjects with a family history of cancer are candidates for preventative programs. Generally, in the context of cancer, the term "prevention" refers to the administration of a drug prior to the onset of signs or symptoms of cancer, particularly in subjects at risk of cancer.
[0126] The term "effective amount" refers to such an amount or dose of the bispecific antibody or its antigen-binding fragment or ADC molecule or composition or combination of the present invention, which, when administered to a patient in a single or multiple doses, produces the intended effect in a patient requiring treatment or prevention. Depending on the intended effect, it may include "therapeutic effective amount" and "preventive effective amount".
[0127] The term "therapeutic effective amount" refers to the amount that effectively achieves the desired therapeutic outcome at the required dose and for the required duration. The therapeutic effective amount of an antibody or ADC can vary depending on various factors such as disease state, individual age, sex, weight, and the ability of the antibody or ADC to elicit the desired response in the individual. Therapeutic effective amount is also a amount in which any toxic or harmful effects of the antibody or ADC are less than the beneficial therapeutic effect. Relative to an untreated subject, "therapeutic effective amount" preferably inhibits measurable parameters (e.g., tumor growth rate, tumor volume, etc.) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, 60%, or 70%, and still more preferably at least about 80% or 90%. The ability of a compound to inhibit measurable parameters (e.g., cancer) can be evaluated in animal model systems that predict efficacy in human tumors. Therapeutic effective amount will vary depending on the type of compound, disease type, disease severity, patient age, etc., but may be adjusted as appropriate by those skilled in the art.
[0128] "Prophylactic effective dose" refers to the amount of medication administered at the required dose for the required duration to effectively achieve the desired preventive outcome. Typically, because prophylactic doses are administered in subjects before or at an early stage of the disease, the prophylactic effective dose is less than the therapeutic effective dose.
[0129] The term "pharmaceutical composition" refers to a composition in a form that allows the biological activity of the active ingredient contained therein to be effective, and which does not contain any additional ingredients that would have unacceptable toxicity to a subject administering the composition.
[0130] The terms “tumor” and “cancer” are used interchangeably in this document to refer to a physiological disorder in mammals in which cell growth is not regulated, encompassing both solid and liquid tumors, as well as malignant and benign tumors, and all precancerous and cancerous cells and tissues.
[0131] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed according to conventional methods and conditions, or as selected according to the product instructions.
[0132] Example 1: Animal Immunization
[0133] (1) Alpaca immunization: 100 μg of PD-L1 antigen (Beijing Baipusaisi, PD1-H5229) was mixed with an equal volume of Freund's adjuvant and injected subcutaneously at multiple points in the neck and forelegs of the alpaca. 20 mL of venous blood was collected from the alpaca before immunization. Subsequent immunizations were performed on days 21, 35, and 49, for a total of 4 immunizations. On day 10 after the last immunization, 20 mL of blood was collected from the alpaca to isolate PBMC samples for subsequent immunization library construction.
[0134] Example 2: Construction of a phage display library for PD-L1 nanobodies
[0135] (1) PBMC isolation: Take blood samples from alpacas after immunization, and use lymphocyte separation medium (GE, 17-1440-02) and density gradient centrifugation to separate and purify lymphocytes in alpaca peripheral blood. After washing the cells with PBS two to three times, they are used for RNA extraction.
[0136] (2) Construction of PD-L1 nanobody library
[0137] Total RNA extraction:
[0138] Take the lymphocytes isolated in (1), add 1 mL of Trizol reagent (INVITROGEN, 15596-018), pipette and mix well to fully lyse the cells, let stand at room temperature for 10 min, add 0.2 mL of chloroform, shake vigorously for 15 s, let stand on ice for 5-10 min, place in a refrigerated centrifuge at 4℃, centrifuge at 12,000 rpm for 10 min, collect the upper aqueous phase, add an equal volume of isopropanol, mix well, let stand at room temperature for 15 min, wait for nucleic acid precipitation, centrifuge at high speed to remove the supernatant, add 1 mL of 75% ethanol (prepared with DEPC water) to wash the RNA precipitate, centrifuge at high speed to remove the supernatant, drain the water, dissolve the RNA in nuclease-free water, and take 1 μL for concentration and purity determination.
[0139] cDNA synthesis:
[0140] Take 20 μg of RNA and synthesize cDNA using the SuperScript™ III First-Strand Synthesis SuperMix (Invitrogen) kit and procedure. Store the synthesized cDNA at -20°C.
[0141] PCR amplification:
[0142] Using the reverse transcription product cDNA as a template, the variable region (VHH) of the camel heavy chain antibody was amplified by Nest-PCR. Table 1 shows the names and sequences of the primers used for amplification.
[0143] Table 1. Primer information used for amplification of the alpaca VHH fragment
[0144]
[0145] The PCR reaction conditions are as follows:
[0146] Round 1:
[0147] cDNA 2 μL; 2×rTaq Mix 25 μL; CALL001 / 001-2 / 001-3 mix (10uM) 1.5 μL; CALL002 (10uM) 1.5 μL; water to bring the total to 50 μL.
[0148] Reaction conditions: 95℃, 5 min; 94℃, 45 s; 56℃, 45 s; 72℃, 45 s per cycle; 72℃, 5 min; amplification 25 cycles.
[0149] Round Two:
[0150] 20 ng of the first-round amplification product; 25 μL of 2×rTaq Mix; 1.5 μL of VHH For (10 uM); 1.5 μL of VHH Back / VHHback-2 / VHH Back-3 mix (10 uM); water to bring the total volume to 50 μL.
[0151] Reaction conditions: 95℃, 5 min; 94℃, 30 s; 56℃, 45 s; 72℃, 35 s per cycle; 72℃, 10 min;
[0152] Amplification 17 cycles.
[0153] After the PCR reaction, the target fragment was recovered using the QIAgen gel purification kit (Qiagen) or PCR purification kit (Qiagen) and their operating procedures. The recovered product was then tested for concentration and purity using Nanodrop 2000 and stored at -20°C.
[0154] (3) Construction of phage display library
[0155] Enzyme digestion and ligation. The VHH fragment and pMECs obtained in (2) were double-digested with restriction endonucleases NotI and PstI (NEB), respectively.
[0156] Vector digestion system:
[0157] pMECS vector 30 μg; PstI 10 μL; NotI 20 μL; Cutsmart (buffer) 30 μL; add H2O to 300 μL; digest overnight at 37 degrees Celsius.
[0158] Fragment digestion system:
[0159] VHH fragment 10 μg; PstI 5 μL; NotI 10 μL; Cutsmart (buffer) 20 μL; add H2O to 200 μL; digest overnight at 37 degrees Celsius.
[0160] The enzyme digestion products of the VHH fragment and pMECs vector were recovered by agarose gel electrophoresis and agarose gel recovery kit (QIAGEN, 20051), and then the enzyme digestion products were ligated.
[0161] The connection system is as follows:
[0162] 1.5 μg pMECs vector; 0.5 μg VHH fragment; 1 μL T4 ligase (NEB); 2 μL 10×T4 ligation buffer; H2O added to 20 μL; ligation overnight at 16°C.
[0163] Transformation: Mix 1 μL of the ligation product with 30 μL of TG1 supercompetent cells, incubate on ice for 5 min, transfer the mixture to an electroporation cuvette, and electroporate at 1.5 kV. After electroporation, add 1 mL of SOC medium, pipette and mix well, then transfer to a 2 mL centrifuge tube. Incubate at 37°C for 1 h, and perform serial dilutions of 10⁻⁶. 2 10 3 10 4 The diluted bacterial culture was spread onto plates and incubated overnight at 37°C. The colony count was calculated the following day, reaching approximately 10. 6 One clone / plate. Repeat the transformation using the same method described above until the number of clones in the library reaches 10. 7 The transformed bacterial culture, which is the antibody phage library, is then added with an equal volume of 50% glycerol and stored at -20°C.
[0164] (4) Detection of diversity of nanobodies in phage display library
[0165] Eighty clones from (3) were randomly selected and sent to 3730 for sequencing. The antibody VHH region sequence was obtained and compared. It was found that only 5 pairs of clone sequences were repeated. Among the 80 clones, 75 clones had different antibody VHH region sequences, accounting for 93.7%, indicating that the antibody library has good diversity.
[0166] (5) Phage amplification and rescue
[0167] The obtained library was amplified, and phage strains carrying PD-L1 nanobodies were rescued using helper phages. The phage library preserved in (3) was inoculated into 100 mL of medium and cultured to the logarithmic growth phase. 20 μL of helper phage (pfu=2×10^12) was added, and the culture was allowed to stand at room temperature for 30 min. After centrifugation at low speed, the precipitate was resuspended in medium and inoculated into 300 mL of medium for overnight culture. The next day, the phage was centrifuged at 3,000 g for 30 min, the supernatant was collected, PEG solution was added to precipitate the phage, and the culture was allowed to stand on ice for 30 min. After centrifugation at 2,200 g for 30 min, the phage library carrying PD-L1 nanobodies was precipitated. The precipitate was resuspended in an appropriate amount of PBS to a titer of 2×10^12. 12 pfu / mL (number of phages per milliliter).
[0168] Example 3: Obtaining high-affinity PD-L1 nanobodies using phage display technology
[0169] (1) Washing of affinity PD-L1 nanobody phage library
[0170] Coat an ELISA plate with 100 ng of antigen and incubate overnight at 4°C. The next day, add 2 × 10⁻⁶ PD-L1 nanoparticle phage obtained above. 11 / well, incubate at room temperature for 2 hours; wash 10 times with PBST, add 100μL of triethylamine elution buffer, incubate at room temperature for 10-30 minutes, and collect the phages, which are the PD-L1 nanobody phage library obtained by affinity washing; take 10μL to infect TG cells and spread on a plate, and use the remaining screened phages for further amplification and rescue.
[0171] (2) Amplification and rescue of phage library after screening
[0172] The amplification and rescue methods are the same as in Example 2 (5). The phage library obtained after the first round of screening is stored at 4°C and the screening is repeated for 2-3 rounds.
[0173] (3) Selection of PD-L1 high affinity nanobody monoclonal antibodies
[0174] As above, 100 ng of PD-L1 antigen was used to coat the ELISA plate as the experimental group. At the same time, an equal number of wells were left uncoated as negative controls. Incubate overnight at 4℃; randomly select single clones from the plates of the 3rd or 4th round of screening and add them to 1 mL of culture medium, incubate at 37℃ until the logarithmic phase, add 1 mM IPTG for induction overnight; the next day, centrifuge to collect bacterial sediment, lyse, centrifuge at 5,000g for 15 min, and collect the supernatant; at the same time, add 2% BSA to the ELISA plate and block at room temperature for 1 h; add the supernatant of single clone lyse to each well of the experimental group and negative control group, incubate at room temperature for 2 h; wash 10 times with PBST, add anti-HA-HRP-tagged antibody (abcam), incubate at room temperature for 1 h; wash 5 times with PBST, add substrate chromogenic reagent, react for 10-20 min, add stop agent, and read the OD450 value using a microplate reader (BioTek, EPOCH); when the absorbance value is greater than 2.1 compared with the control well, it is judged as a positive clone. In this example, a total of 9 nanobodies with strong specific affinity for PD-L1 were screened.
[0175] Example 4: Induction and purification of PD-L1 nanobodies
[0176] (1) Induced expression of PD-L1 nanobodies
[0177] Nine PD-L1 nanobody sequence monoclonal antibodies were selected and inoculated into 10 mL of ampicillin-containing medium, and cultured overnight at 37°C and 220 rpm. The next day, 2 mL of the overnight culture was inoculated into 200 mL of ampicillin-containing medium and cultured at 37°C and 220 rpm until the logarithmic growth phase (OD200). 600 The concentration of the bacterial culture was 0.6-0.8 g (presumably referring to a concentration of 0.6-0.8 g), and IPTG was added overnight to induce nanobody expression. The next day, the bacterial cell pellet was collected, and the cells were lysed using a hypotonic method. The supernatant was then collected by high-speed centrifugation for subsequent protein purification.
[0178] (2) Purification of PD-L1 nanobody
[0179] Purified PD-L1 nanobodies were obtained using an affinity purification column (His-Trap 1 mL, GE). The Ni column was first washed with ultrapure water, then with affinity A buffer. The supernatant was added to the purification column at a flow rate of 1 mL / min. Impurities were washed away with an appropriate volume of affinity A1 buffer (30 mM imidazole) until the OD280 was below 0.0001. The target protein was then eluted with 10 volumes of elution buffer (150 mM imidazole). The purified target protein was analyzed by 12% SDS-PAGE using a vertical electrophoresis system (Bio-rad, Mini PROTEAN Tetra System) to assess the expression and purification of the PD-L1 nanobodies. Figure 1As shown in the figure, the nanobody bands are approximately 15 kDa in size, with a purity >95%, and all nine nanobody strains were successfully and correctly expressed.
[0180] Example 5: Competitive ELISA analysis of the blocking effect of PD-L1 nanobody on PD-1 / PD-L1
[0181] 100 ng of PD-L1 protein was coated onto an ELISA plate and incubated overnight at 4°C. The plate was washed three times with PBST. 200 μL of 2% BSA was added to each well and incubated at room temperature for 2 hours. The plate was washed three times with PBST. The purified nanobody and negative control antibody were diluted to concentrations of 3 μg / mL, 0.3 μg / mL, and 0.03 μg / mL, respectively, and mixed with 4 μg / mL PD-1. A blank control (containing only 4 μg / mL PD-1, without antibody) was added to the wells and incubated at room temperature for 1 hour. The plate was washed six times with PBST. 100 μL / well of 2000-fold diluted anti-HA and HRP (abcam) was added and incubated at room temperature for 1 hour. The plate was washed six times with PBST. 100 μL of TMB chromogenic buffer was added and incubated for 10 minutes. An equal volume of stop reagent was added. The plate was read at OD450 using a microplate reader (BioTek, EPOCH). ELISA results (…) Figure 2 The results showed that the PD-L1 nanobodies VHH15-1, VHH15-2, VHH15-3, VHH15-4 and VHH15-8 can effectively block the binding of PD-1 to PD-L1, exhibiting competitive inhibitory effects.
[0182] The amino acid sequences of these nine nanobodies are as follows:
[0183] Table 2 Sequence of PD-L1 nanobodies
[0184]
[0185] Note: Italics and underlines are CDRs; CDR areas are divided according to the IMGT numbering scheme.
[0186] Table 3. CDR sequences of PD-L1 nanobodies
[0187]
[0188] VHH CDR3 (SEQ ID NO: 48): AARX1GMMALATHRALYEX2, where X1 is N or R and X2 is E or Y.
[0189] Table 4. FR sequences of PD-L1 nanobodies
[0190]
[0191] Example 6: ELISA analysis of the affinity between PD-L1 nanobody and PD-L1
[0192] 100 ng of PD-L1 antigen (Beijing Baipusaisi, PD1-H5229) was coated onto an ELISA plate and incubated overnight at 4°C. The plate was washed three times with PBST (0.05%). 200 μL of 2% BSA was added to each well and incubated at room temperature for 2 hours. The plate was washed three times with PBST. The five purified nanobodies that demonstrated competitive efficacy in Example 5 were serially diluted. The initial concentration was 1.5 μg / mL (~100 nM), and each well was serially diluted 5-fold for a total of eight concentration gradients. Each gradient was repeated three times, with 100 μL added to each well, and incubated at room temperature for 1 hour. The plate was washed six times with PBST, and 100 μL / well of anti-HA and HRP (abcam) diluted 2000-3000 times was added, and the plate was incubated at room temperature for 1 hour. Wash 6 times with PBST, add 100 μL of TMB chromogenic solution (abcam), develop for 10 min, and add an equal volume of TMB stop buffer (abcam) to stop the OD450 reading.
[0193] ELISA test results are as follows ( Figure 3 The results showed that all five PD-L1 nanobodies had good affinity for PD-L1. The half-maximal effective concentrations (EC50) of VHH15-1, VHH15-2, VHH15-3, VHH15-4 and VHH15-8 were 0.9269 nM, 1.305 nM, 10.61 nM, 2.436 nM and 1.664 nM, respectively.
[0194] Depend on Figure 4 Sequence alignment results show that the five PD-L1 nanobodies involved in this invention exhibit extremely high amino acid sequence homology. The amino acid sequence similarity of VHH15-1, VHH15-2, VHH15-3, and VHH15-8 is over 90%, while the VHH15-4 sequence shows over 86% similarity to the other four antibodies. Furthermore, the CDR3 sequences of the four antibodies are almost identical, essentially all being AARNGMMALATHRALYEY, with only one amino acid difference between VHH15-3 and VHH15-1. Simultaneously, the five antibody sequences show extremely high similarity in FR1, CDR1, FR2, CDR2, FR3, and FR4. The five antibodies exhibit similar effects in subsequent antibody affinity constants and cell blocking activities, indicating that the highly homologous portions of these five antibody sequences play a decisive role in PD-L1 antibody activity, while the sequence differences have almost no impact on the overall antibody efficacy.
[0195] Example 7: Bivalent modification, eukaryotic expression and purification of nanobodies
[0196] Five PDL1 nanobodies with PD-1 / PD-L1 blocking activity screened in Example 5 were bivalently modified: from 5' to 3', they were nanobodies and IgG4 Fc, respectively. Human IgG4 Fc gene sequences were fused to synthesize the genes, and the synthesized gene sequences corresponded to the fusion proteins VHH15-1-FC, VHH15-2-FC, VHH15-3-FC, VHH15-4-FC and VHH15-8-FC.
[0197] IgG4 Fc sequence (SEQ ID NO: 50)
[0198] APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK;
[0199] IgG4 partial hinge region sequence (SEQ ID NO: 49)
[0200] PPCPSCP
[0201] Connecting subsequence (SEQ ID NO: 51)
[0202] EPKIPQPQPKPQPQPQPQPKPQPKPEPECTCPKCP
[0203] The synthesized gene sequence was subcloned into the expression vector pcMV3 (SinoBiological, CV011) using seamless cloning PCR technology (specific procedures are described in the Hieff Clone® plus One Step Cloning Kit manual). The recombinant single-domain antibody VHH-FC fusion protein plasmid was transfected into HEK293T cells (ATCC, CRL-11268) for expression. The recombinant expression plasmid was diluted with PBS, and PEI (polyethylenimine) solution required for transformation was added. After mixing, the mixture was added to the HEK293T cell suspension and incubated at 37°C, 8% CO2, and ≥80% relative humidity at 150 rpm. After 5-6 days of culture, the transient expression culture supernatant was collected, and a portion of the supernatant was used for in vitro cell viability assays (Example 8). The remaining supernatant was used for subsequent protein purification, which was performed by protein A affinity chromatography (purchased from GE) to obtain the target PD-L1-VHH-FC fusion proteins VHH15-1-FC, VHH15-2-FC, VHH15-3-FC, VHH15-4-FC, and VHH15-8-FC. Figure 5 ).
[0204] Example 8: In vitro efficacy evaluation of PD-L1 bivalent nanobody based on cytolucanase method
[0205] PD-L1 target cells (GenScript, M00613) were seeded into 96-well plates at 10^5 cells per well and cultured overnight at 37°C with 5% CO2. The next day, the culture plates were removed, and the supernatant of 293T eukaryotic expression cell culture from Example 7, along with the positive control (Avelumab) and the negative blank control (293T blank cell culture supernatant), were diluted 6-fold, 24-fold, 96-fold, 384-fold, 1536-fold, and 6144-fold, respectively. These serially diluted samples were added to the culture plates, followed by 10^5 PD-1 effector cells (GenScript, M00612). The plates were cultured at 37°C with 5% CO2 for 6 hours. Luciferase assay reagent (Promega, G7940) was added, and the results were read using Phera Star. Data analysis was performed based on the assay results, as shown in the table below:
[0206] Table 5. Phera Star readings for PD-L1 bivalent nanobodies
[0207]
[0208] The results showed that, compared with the negative control, VHH15-1-FC, VHH15-2-FC, VHH15-3-FC, VHH15-4-FC, and VHH15-8-FC effectively blocked the binding of PD-L1 target cells to PD-1 effector cells, while VHH15-5-FC, VHH15-6-FC, VHH15-7-FC, and VHH15-9-FC failed to block the binding of PD-L1 target cells to PD-1 effector cells. Furthermore, compared with the positive control (Avelumab), VHH15-8-FC exhibited a stronger inhibitory effect.
[0209] Example 9: Determination of the affinity constant of PD-L1 bivalent nanobody by SPR method
[0210] The protein A chip was used to sequentially capture the bivalent nanobody protein solution and the positive control drug (Tecentriq) for 30 seconds at a flow rate of 10 μL / min. The hPD-L1 antigen was then diluted with PBST (0.005%) to create a suitable concentration gradient. In this example, the gradient was 2-fold from approximately 2.7 μg / mL (100 nM), resulting in 6-8 concentration gradients. Each injection lasted 120 seconds, followed by dissociation for 240 seconds, and then regeneration with 10 mM pH 2.0 Gly-HCl. This cycle was repeated until all concentration gradients were injected. After the program ran, the Biacore T200 (GE) instrument's built-in analysis program was used for fitting analysis to obtain the nanobody affinity constants (Table 1). The results showed that the KD constants of the PD-L1 nanobody in this example were all above 10. -10 M has a similar affinity to the positive control drug Tecentriq, both being below 0.5 nM, indicating extremely strong affinity.
[0211] Table 6. Affinity constants of five PD-L1 bivalent nanobodies
[0212]
[0213] Example 10: Activation effect of PDL1 monoclonal antibody on PBMCs
[0214] 5 ng / mL OKT3 (EBIOSCIENCE, 16-0037-81) was pre-coated into 96-well cell culture plates (flat bottom), with 3 wells left uncoated as blank wells. The plates were incubated overnight at 4°C. The next day, the coating solution was discarded, and the plates were washed twice with 200 μL PBS. Then, 1 × 10⁻⁶ ng / mL OKT3 was added to each of the OKT3-coated wells and the uncoated blank wells. 5PBMCs (Redbury, 1501-10M) were used. Simultaneously, the detection group was supplemented with 2.5 μg / mL VHH15-8-FC, the control group with 2.5 μg / mL Tecentriq, the positive control group with 1000 pg / mL INF-γ, and the negative control group with DPBS. Blank wells without OKT3 coating were supplemented with DPBS as the blank group. Each group was repeated in triplicate. The cells were placed in a cell culture incubator at 37°C and 5% CO2 for 4 days. The supernatant was then collected, and the serum IFN-γ secretion level was detected using an IFN-γ ELISA kit (R&D, DIF50).
[0215] Test results are shown Figure 6 It can be seen that the PD-L1 bivalent single-domain antibody VHH15-8-FC, in combination with the CD3 antibody OKT3, can enhance the secretion of IFN-γ by PBMCs, that is, enhance the activation of PBMCs, and its effect is not significantly different from that of the positive drug Tecentriq.
[0216] Example 11: Mouse Tumor Drug Efficacy Experiment
[0217] Mouse colon cancer cell line MC38-hPDL1 cells were resuscitated and cultured. MC38-hPDL1 cells in the logarithmic growth phase were collected, and cell viability was determined to be above 95%. After removing the culture medium and washing twice with PBS, the cells were inoculated into the right forelimb of a C57BL / 6-hPDL1 (Jicui Yaokang) cell line at a dose of 1×10⁻⁶. 6 Mice were inoculated with 100 μL / mouse. On day 7 post-inoculation, when the average tumor volume reached 95.34 mm³, mice were selected for further study and divided into three groups (Group 1 - IgG4 negative control group, Group 2 - Tecentriq positive control group, Group 3 - VHH15-8-FC test group), with 6 mice in each group. Day 0 was defined as the day of grouping. Drug administration began on day 0. The IgG and Tecentriq groups received a dose of 1.5 mpk (1.5 mg per kg of mouse weight) per mouse; the VHH15-8-FC group received a dose of 0.8 mpk per mouse. Drugs were administered twice weekly, with intervals of 3 or 4 days, for a total of 6 administrations. Tumor volume inhibition was observed.
[0218] Test results as follows Figure 7 As shown, compared with the IgG4 negative control group, VHH15-8-FC has a significant tumor-inhibiting effect, and can achieve a similar inhibitory effect to Tecentriq with a lower drug dose of 0.8 mpk, showing better overall performance in terms of drug dosage and tumor inhibition effect.
[0219] Example 12: Species Cross-Reaction of PD-L1 Nanobodies
[0220] Add 100 ng of human PD-L1 (ACROBiosystems Beijing), mouse PD-L1 (ACROBiosystems Beijing), and cynomolgus PD-L1 (ACROBiosystems Beijing) to each well of an ELISA plate and incubate overnight at 4°C. Wash three times with 0.05% PBST. Add 200 μL of 2% BSA to each well and incubate at room temperature for 2 h. Wash three times with PBST. Five nanobodies—PD-L1-VHH15-1, PD-L1-VHH15-2, PD-L1-VHH15-3, PD-L1-VHH15-4, and PD-L1-VHH15-8—were diluted to 1.5 μg / mL and then added 100 μL to each well of an ELISA plate coated with human PD-L1, mouse PD-L1, and cynomolgus PD-L1, respectively. The plates were incubated at room temperature for 1 hour. A negative control was added to wells without antigen coating. The plates were washed six times with PBST, and then 100 μL / well of 2000-3000 times diluted anti-HA and HRP (abcam) were added. The plates were incubated at room temperature for 1 hour. Wash 6 times with PBST, add 100 μL of TMB chromogenic solution (abcam), develop for 10 min, add an equal volume of TMB stopbuffer (abcam) to stop the chromogenic process, and read the OD450 value using a microplate reader (BioTek).
[0221] The results showed that, compared with the results of the uncoated (negative control blank) test, all five PD-L1 nanobodies (VHH15-1, VHH15-2, VHH15-3, VHH15-4 and VHH15-8) could specifically bind to human PD-L1 and monkey PD-L1, but could not bind to mouse PD-L1.
[0222] Table 7. OD450 readings of five PD-L1 bivalent nanobodies
[0223]
[0224] Example 13: Bispecific antibody modification of PD-L1 nanobodies
[0225] 1) Molecular design
[0226] The PD-L1 nanobody (VHH15-8) in this invention and the CTLA-4 target nanobody (VHH1) in invention P20017820C were combined to design an IgG-like bispecific antibody. Figure 8There are three main types. The first is a symmetrical configuration, in which two target nanobodies are respectively linked to the N-terminus and C-terminus of Fc (BsAb-F1); the second is a symmetrical "Y"-shaped structure, in which two target nanobodies are tandemly linked to the N-terminus of Fc (BsAb-F2); the third is an asymmetrical "Y"-shaped structure, in which two target nanobodies are bivalently linked to both ends of Fc and specifically combined using the Knob-in-hole technique (Spiess et al., 2013; Ridgway et al., 1996) to form a bispecific antibody (BsAb-F3).
[0227] The amino acid sequence of the CTLA-4 nanobody (SEQ ID NO: 36):
[0228] QVQLQESGGGLVQAGGSLRLSCEVSGDITNFNAMGWGRQAPGNKRELVATIGQTEGSGYADSVKGRFTISTDSARNTVYLQMNSLKPEDTAVYYCYAFRDGANQLWGQGTQVTVSS
[0229] CDR1: GDITNFNA (SEQ ID NO: 37);
[0230] CDR2: IGQTEGS (SEQ ID NO: 38);
[0231] CDR3: YAFRDGANQL (SEQ ID NO: 39).
[0232] BsAb-F1 amino acid sequence (SEQ ID NO: 32)
[0233] QVQLQESGGGLVQTGGSLRLSCVSSGRERTAMGWFRQAPGKERELVGSITSTGGDTYIADAMQGRFTISRDNAKNTVYLQMNNLRPEDTAVYYCAARNGMMALATHRALYEYWGQGTQVTVSSPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGKEPKIPQPQPKPQPQPQPQPKPQPKPEPECTCPKCPQVQLQESGGGLVQAGGSLRLSCEVSGDITNFNAMGWGRQAPGNKRELVATIGQTEGSGYADSVKGRFTISTDSARNTVYLQMNSLKPEDTAVYYCYAFRDGANQLWGQGTQVTVSS
[0234] BsAb-F2 amino acid sequence (SEQ ID NO: 33)
[0235] QVQLQESGGGLVQTGGSLRLSCVSSGRERTAMGWFRQAPGKERELVGSITSTGGDTYIADAMQGRFTISRDNAKNTVYLQMNNLRPEDTAVYYCAARNGMMALATHRALYEYWGQGTQVTVSSEPKIPQPQPKPQPQPQPQPKPQPKPEPECTCPKCPQVQLQESGGGLVQAGGSLRLSCEVSGDITNFNAMGWGRQAPGNKRELVATIGQTEGSGYADSVKGRFTISTDSARNTVYLQMNSLKPEDTAVYYCYAFRDGANQLWGQGTQVTVSSPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0236] BsAb-F3 heavy chain 1 amino acid sequence (SEQ ID NO: 34)
[0237] QVQLQESGGGLVQTGGSLRLSCVSSGRERTAMGWFRQAPGKERELVGSITSTGGDTYIADAMQGRFTISRDNAKNTVYLQMNNLRPEDTAVYYCAARNGMMALATHRALYEYWGQGTQVTVSSEPKIPQPQPKPQPQPQPQPKPQPKPEPECTCPKCPQVQLQESGGGLVQTGGSLRLSCVSSGRERTAMGWFRQAPGKERELVGSITSTGGDTYIADAMQGRFTISRDNAKNTVYLQMNNLRPEDTAVYYCAARNGMMALATHRALYEYWGQGTQVTVSSPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0238] BsAb-F3 heavy chain 2 amino acid sequence (SEQ ID NO: 35)
[0239] QVQLQESGGGLVQAGGSLRLSCEVSGDITNFNAMGWGRQAPGNKRELVATIGQTEGSGYADSVKGRFTISTDSARNTVYLQMNSLKPEDTAVYYCYAFRDGANQLWGQGTQVTVSSEPKIPQ PQPKPQPQPQPQPKPQPKPEPECTCPKCPQVQLQESGGGLVQAGGSLRLSCEVSGDITNFNAMGWGRQAPGNKRELVATIGQTEGSGYADSVKGRFTISTDSARNTVYLQMNSLKPEDTAVYY CYAFRDGANQLWGQGTQVTVSSPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0240] Example 14: Expression and purification of bispecific nanobodies
[0241] The designed bispecific nanobody gene sequence was synthesized by Beijing Yiqiao Biotechnology Co., Ltd., and the synthesized gene was directly subcloned into a customized eukaryotic expression vector (SinoBiological, CV011). The recombinant plasmid was transfected into HEK293T cells (ATCC, CRL-11268) for expression. The recombinant expression plasmid was diluted with PBS, and PEI (polyethylenimine) solution required for transformation was added. After mixing, the mixture was added to the HEK293T cell suspension and incubated at 37°C, 8% CO2, and ≥80% relative humidity at 150 rpm. After 5-6 days of culture, the transient expression culture supernatant was collected and purified by protein A affinity chromatography (purchased from GE) to obtain the target antibody.
[0242] The results show that ( Figure 9The expression yields of the three bispecific nanobodies, from highest to lowest, were: BsAb-F1 (300 mg / L, 2.68 μmol / L), BsAb-F2 (~210 mg / L, 1.88 μmol / L), and BsAb-F3 (~207 mg / L, 1.85 μmol / L); protein purity was 90% or higher, and the target band was approximately 115 KD. The parental monoclonal antibodies VHH15-8-FC and VHH1-FC showed similar expression yields (molar yields) of approximately 80 KD.
[0243] Example 15: Detection of Bispecific Nanobody EC50
[0244] Add 100 ng of PD-L1, his tag or CTLA-4, his tag (Beijing Baipusaisi) to each well of the ELISA plate and incubate overnight at 4°C. The next day, wash three times with PBST, add 200 μL of 2% BSA to each well, and incubate at room temperature for 2 hours. Wash three times with PBST, then add a series of serially diluted bispecific nanobody and its parent monoclonal antibody, Tecentriq and Yervoy as positive controls. The specific dilution concentrations are: starting at 5 nM, followed by 5-fold serial dilutions for a total of 8 concentration gradients, with each gradient repeated in 3 wells, 100 μL per well, and incubate at room temperature for 1 hour. Wash 5-6 times with PBST, add 100 μL of diluted anti-human IgG, HRP (A80-304P, Bethyl) to each well, and incubate at room temperature for 1 hour. Wash 5-6 times with PBST, add 100 μL of TMB chromogenic solution to each well, and incubate at room temperature in the dark for 10 minutes. Add an equal volume of TMB stop solution. The buffer is used to terminate color development, and OD450 readings and statistical analysis are performed.
[0245] ELISA results (Table 9) showed that BsAb-F1 had higher affinity for both PD-L1 and CTLA-4 than its parent nanomonoantibodies VHH15-8-FC and VHH1-FC; and its EC50 binding to PD-L1 and CTLA-4 was similar (ratio close to 1), indicating little or no interference between the VHH binding arms of the two targets or between the VHH binding arm and the Fc domain. However, the EC50 binding to CTLA-4 of BsAb-F2 and BsAb-F3 was lower than that of their parent monoclonal antibodies, and also lower than that of PD-L1. This may be because the CTLA-4-VHH arm in each antibody is sterically hindered by the PD-L1-VHH arm in series with it, or by another CTLA-4-VHH arm in series with it.
[0246] Table 8. EC50 of bispecific nanobody binding to PD-L1 and CTLA-4
[0247]
[0248] Note: "n / a" means not applicable.
[0249] Example 16: Detection of KD Affinity for Bispecific Nanobodies
[0250] The antigen was diluted to 2 μg / mL, and then the parameters were set on the Biacore T200 (GE) instrument to inject the antigen at a flow rate of 10 μL / min for 30-60 s, so that the NTA chip captured about 60 RU of His-tagged antigen. Next, the antibody to be tested was diluted 2-fold with 0.05% HBS-T injection buffer, with the dilution concentrations being 5, 2.5, 1.25, 0.625, 0.3125, and 0.15625 nM, respectively. Each concentration was injected for 120 s, followed by dissociation for 240 s. 3.5M EDTA was injected at 30 μL / min for 60 s, followed by regeneration. Nickel chloride was injected for 60 s at 10 μL / min. Then, steps 1-4 were repeated until all concentration gradients were injected. After the program ran, the instrument's built-in analysis program was used for fitting analysis.
[0251] The results are shown in Table 10. The dissociation constants (KD) of the three bispecific nanobodies bound to the PD-L1 target were all in the pmol level. Among them, BsAb-F1 and BsAb-F2 showed similar affinities to Tecentriq, almost exceeding the instrument's detection limit, at 1 pmol, 6 pmol, and 3 pmol, respectively. The KD values of the three bispecific nanobodies bound to PD-L1 were all higher than those of the parent monoclonal antibody VHH15-8-FC (87 pmol), indicating that the affinity of the PD-L1 target nanobodies in the three configurations was not affected by steric hindrance. However, the affinity of the three bispecific nanobodies for CTLA-4 was weaker than that of the positive antibody Yervoy. Furthermore, except for BsAb-F1, the affinity of the other two bispecific nanobodies for CTLA-4 was lower than that of their parent monoclonal antibody VHH1-FC, consistent with the ELISA results. These results further demonstrate that the two target binding arms of BsAb-F1 are less affected by steric hindrance, exhibiting a more significant structural advantage. In addition, BsAb-F1 also exhibits strong binding activity to mouse-derived CTLA-4 (KD: 0.776 nM, Table 10).
[0252] In summary, among the three molecular configurations, BsAb-F1 exhibits higher expression yield and greater affinity for binding to both target antigens, demonstrating a clear structural advantage.
[0253] Table 9. KD values of bispecific nanobody binding to PD-L1 and CTLA-4
[0254]
[0255] Notes: Ligand - ligand; Analyte - analyte; kon - binding constant; koff - dissociation constant; KD - binding-dissociation equilibrium constant, KD = koff / kon; Chi2 - deviation between measured and fitted values, the smaller the value, the smaller the deviation.
[0256] Example 17: In vitro cell function detection of bispecific nanobodies
[0257] 10,000 CHO-K1 / aAPC / PD-L1 stable cell lines (GenScript, M00613) were seeded into each well of a 384-well plate and cultured overnight at 37°C with 5% CO2. The next day, the supernatant was removed, and 20 μL of serially diluted BsAb-F1 and Tecentriq samples were added to each well. Then, 40,000 Jurkat / NFAT-Luc / PD-1 effector cells (GenScript, M00612) were added to each well and incubated at 37°C for 6 hours. 30 μL of Luciferase assay reagent (Genscript, L00877C-100) was added to each well, and the assay results were read using a ThermoFisher (Varioskan Lux) microplate reader to analyze the blocking effect of BsAb-F1 on PDL1. Figure 10 ).
[0258] In addition, 40,000 Jurkat / CD28 (GenScript, M00611) cells were added to each well of a 384-well plate (white plate, flat bottom), using a culture medium containing 5 μg / mL PHA (Promega, G7940). Then, 20,000 CHO-K1 / CD80 (GenScript, M00614) cells, 20 μL of 2 μg / mL CTLA-4 solution (Genscript, Z03373), and 20 μL of serially diluted BsAb-F1 sample solution were added to each well. The plate was incubated at 37°C for 24 h. The supernatant was then collected, and the IL-2 content in the supernatant was detected using an IL-2 detection kit (Cisbio, 62HIL02PET).
[0259] Test results ( Figure 10 The study found that BsAb-F1 had a similar blocking effect to Tecentriq (0.3880 μg / mL vs. 0.3115 μg / mL), exhibiting a strong blocking effect; its blocking effect on CTLA-4 was weaker than that of Yervoy, which is consistent with the expectation of a strong PD-L1 binding arm and a weak CTLA-4 binding arm, both of which can stimulate lymphocytes to secrete IL-2.
[0260] Example 18: Pharmacodynamic Detection of Bispecific Nanobody in Mice
[0261] Six- to seven-week-old MC38-tumor-bearing C57BL / 6-PDL1 humanized mice (source: Jiangsu Jicui Biotechnology) were randomly divided into four groups (G1, G2, G3, G4), with six mice in each group. The day of grouping was defined as D0. On days 0, 3, 7, 10, 14, 17, 21, and 24, mice were intraperitoneally injected with IgG4 3 mpk (G1), BsAb-F1 0.3 mpk (G2), BsAb-F1 1 mpk (G3), and BsAb-F1 3 mpk (G4), respectively. On days 0, 3, 7, 10, 14, 17, 21, 24, 28, and 34, tumor size was observed, and mouse weight was recorded. Tumor volume was calculated as: tumor volume (mm3) = 0.5 × (tumor long axis × tumor short axis²). At the experimental endpoint (day 34), mice were euthanized, tumors were isolated, photographed, and weighed.
[0262] result( Figure 11 It was found that treatment with three doses of BsAb-F1 significantly inhibited tumor growth, with tumor volume inhibition rates (TGItv) of 37.8%, 71.03%, and 94.75%, respectively, showing a dose-dependent effect. Figure 11 (A); meanwhile, there was no significant difference in growth weight between the mice and the IgG4 control group (A). Figure 11 No other significant adverse reactions were observed during the experiment, indicating that our bispecific antibody has minimal side effects. At the experimental endpoint, mouse tumors were isolated and weighed. It was found that at doses of 1 mg / kg and 3 mg / kg, the tumor weight in mice treated with BsAb-F1 was significantly lower than that in the control group (P < 0.01). Figure 11 D&E).
[0263] While specific embodiments of the present invention have been described above, those skilled in the art should understand that these are merely illustrative examples, and various changes or modifications can be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. A nanobody against PD-L1, characterized in that, The nanobody contains a VHH domain, which contains CDR1, CDR2 and CDR3; wherein the amino acid sequences of CDR1-CDR3 are shown in SEQ ID NO: 4, 8 and 10, respectively.
2. The nanobody as described in claim 1, characterized in that, The VHH domain further comprises FR1, FR2, FR3, and FR4; FR1 comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 12; and / or, FR2 comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 14; and / or, FR3 comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 21; and / or, FR4 comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
22.
3. The nanobody as described in claim 2, characterized in that, The FR1-FR4 respectively contain amino acid sequences as shown in SEQ ID NO:12, 14, 21 and 22.
4. The nanobody according to any one of claims 1-3, characterized in that, The nanobody comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
23.
5. The nanobody as described in claim 4, characterized in that, The nanobody contains an amino acid sequence as shown in SEQ ID NO:
23.
6. A fusion protein, characterized in that, The fusion protein comprises a nanobody as described in any one of claims 1-5 and a heavy chain constant region, wherein the fusion protein is a heavy chain antibody.
7. The fusion protein as described in claim 6, characterized in that, The heavy chain constant region is a heavy chain constant region of human IgG1, IgG2, IgG3 or IgG4; and / or, the heavy chain constant region contains CH2-CH3 or CH1-CH2-CH3.
8. The fusion protein as described in claim 6, characterized in that, The heavy chain constant region contains an amino acid sequence that has at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
50.
9. The fusion protein as described in claim 8, characterized in that, The heavy chain constant region contains the amino acid sequence shown in SEQ ID NO:
50.
10. A bispecific recombinant protein, characterized in that, The bispecific recombinant protein comprises a first protein functional region and a second protein functional region targeting PD-L1; the first protein functional region is a nanobody as described in any one of claims 1-5; The second protein functional region targets CTLA-4; the second protein functional region is sdAb, which contains a VHH' domain.
11. The bispecific recombinant protein as described in claim 10, characterized in that, The VHH' comprises CDR1', CDR2' and CDR3'; wherein the amino acid sequences of CDR1'-CDR3' are as shown in SEQ ID NO: 37-39, respectively.
12. The bispecific recombinant protein as described in claim 11, characterized in that, The VHH' contains an amino acid sequence that has at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
36.
13. The bispecific recombinant protein as described in claim 11, characterized in that, The VHH' contains an amino acid sequence as shown in SEQ ID NO:
36.
14. The bispecific recombinant protein according to any one of claims 10-13, characterized in that, The bispecific recombinant protein includes constant regions selected from human IgG1, IgG2, IgG3, IgG4 and their variants, wherein the variants have at least 80% sequence identity compared to the sequences from which they originate.
15. The bispecific recombinant protein as described in claim 14, characterized in that, The bispecific recombinant protein includes a constant region derived from human IgG4 or a variant thereof.
16. The bispecific recombinant protein as described in claim 14, characterized in that, The variant is a constant region of human IgG4 or human IgG1 with knob mutation and hole mutation.
17. The bispecific recombinant protein according to any one of claims 10-13, characterized in that, The bispecific recombinant protein comprises two chains having one of the following structures: (1) Chain I: VHH-CH2-CH3-VHH'; Chain II: VHH-CH2-CH3-VHH'; (2) Chain I: VHH-VHH'-CH2-CH3; Chain II: VHH-VHH'-CH2-CH3; (3) Chain I: VHH-VHH-CH2-CH3; Chain II: VHH'-VHH'-CH2-CH3; Among them, the C end of VHH or VHH' is connected to the N end of the constant region through a hinge region; the N end of VHH or VHH' is connected to the C end of the constant region through a connector; VHH and VHH' are connected to each other through a connector.
18. The bispecific recombinant protein as described in claim 17, characterized in that, The linker comprises an amino acid sequence as shown in SEQ ID NO: 51, and / or the hinge region comprises an amino acid sequence as shown in SEQ ID NO:
49.
19. The bispecific recombinant protein as described in claim 14, characterized in that, The two chains of the bispecific recombinant protein are identical and contain an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 32 or 33; or, the two chains of the bispecific recombinant protein are different, with chain I containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 34, and chain II containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
35.
20. The bispecific recombinant protein as described in claim 19, characterized in that, The two chains of the bispecific recombinant protein are identical and contain the amino acid sequence shown in SEQ ID NO: 32 or 33; or, the two chains of the bispecific recombinant protein are different, with chain I containing the amino acid sequence shown in SEQ ID NO: 34 and chain II containing the amino acid sequence shown in SEQ ID NO:
35.
21. An isolated nucleic acid, characterized in that, The nucleic acid encodes a nanobody as described in any one of claims 1-5, a fusion protein as described in any one of claims 6-9, or a bispecific recombinant protein as described in any one of claims 10-20.
22. A recombinant vector, characterized in that, The recombinant vector comprises the nucleic acid as described in claim 21.
23. The recombinant vector as described in claim 22, characterized in that, The recombinant vector is selected from viral vectors and non-viral vectors; the non-viral vector is selected from plasmids, linear DNA fragments, and RNA.
24. A transformant, characterized in that, The transformant comprises the nucleic acid as described in claim 21, or the recombinant vector as described in claim 22; and the transformant is not an animal or plant species.
25. The transformant as described in claim 24, characterized in that, The host cell of the transformant is a prokaryotic cell or a eukaryotic cell.
26. The transformant as described in claim 25, characterized in that, The eukaryotic cells are yeast cells or mammalian cells.
27. A method for preparing nanobodies, fusion proteins, or bispecific recombinant proteins, characterized in that, The method includes culturing the transformant as described in any one of claims 24-26 under suitable conditions to obtain the nanobody, fusion protein, or bispecific recombinant protein from the culture.
28. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises a nanobody as described in any one of claims 1-5, a fusion protein as described in any one of claims 6-9, or a bispecific recombinant protein as described in any one of claims 10-20, and a pharmaceutically acceptable carrier.
29. A reagent kit, characterized in that, The kit comprises a nanobody as described in any one of claims 1-5, a fusion protein as described in any one of claims 6-9, a bispecific recombinant protein as described in any one of claims 10-20, a nucleic acid as described in claim 21, a recombinant vector as described in claim 22 or 23, a transformant as described in any one of claims 24-26, or a pharmaceutical composition as described in claim 28.
30. A method for detecting PD-L1, characterized in that, The method includes contacting the nanobody as described in any one of claims 1-5, the fusion protein as described in any one of claims 6-9, or the kit as described in claim 29 with the sample to be tested; The method described is not for diagnostic and / or therapeutic purposes.
31. The use of the nanobody as described in any one of claims 1-5, the fusion protein as described in any one of claims 6-9, the bispecific recombinant protein as described in any one of claims 10-20, the nucleic acid as described in claim 21, the recombinant vector as described in claim 22 or 23, the transformant as described in any one of claims 24-26, and the pharmaceutical composition as described in claim 28 in the preparation of a medicament for the prevention and / or treatment of tumors; The tumors are selected from liver cancer, breast cancer, bladder cancer, sarcoma, cervical cancer, renal cell carcinoma, ovarian cancer, colon cancer, lung cancer, melanoma, and stomach cancer.
Citation Information
Patent Citations
Heterodimeric FC (fragment crystallizable) modification method based on charge network and preparation method of heterodimeric proteins
CN102558355B
PD-L1 binding molecule and application thereof
CN116063518A
Anti-PD-l1 nanobody and trifunctional fusion protein
WO2022105832A1
